Nature Medicine, Published online: 17 April 2025; doi:10.1038/s41591-025-03718-3
In a patient with treatment-refractory idiopathic inflammatory myositis, re-infusion of CD19 CAR-T cells following disease relapse led to the development of anti-CD19 CAR T cells and no clinical improvement, with drug-free remission induced again after treatment with BCMA CAR-T cells
